Abstract Library

#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience

Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Khan M, Aldridge R, Walker R, Toumpanakis C, Caplin M,

Keywords: Lanreotide autogel, carcinoid syndrome, neuroendocrine tumor, somatostatin analogue ,